GlassScriptPhysician profile
Andrew Michael Portteus
NPI 1558323600
$2,458.47
in general payments reported to CMS, 2019-2025
15 companies · $1,161 in 2025
The $1,161 reported for 2025 was more than what 87% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $198 · 2023: $244 · 2024: $855 · 2025: $1,161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,255 · Education: $5.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,255.29 |
| Education | $5.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $668.55 | 2022-2025 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $285.59 | 2024-2025 | Auvelity |
| Collegium Pharmaceutical, INC. | $284.44 | 2025 | Jornay Pm |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $195.04 | 2024-2025 | Caplyta |
| Abbvie INC. | $166.42 | 2023-2025 | |
| Ironshore Pharmaceuticals INC. | $161.08 | 2022-2024 | Jornay Pm |
| Corium, LLC | $155.88 | 2022-2025 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $152.51 | 2022-2025 | Rexulti |
| Bausch Health US, LLC | $130.32 | 2022-2025 | Aplenzin, Wellbutrin |
| Tris Pharma INC | $76.77 | 2022-2025 | Dyanavel Xr |
| Vertical Pharmaceuticals, LLC | $73.20 | 2024-2025 | Relexxii |
| Takeda Pharmaceuticals U.S.A., INC. | $35.59 | 2024 | Trintellix |
| Noven Therapeutics, LLC | $32.92 | 2023-2025 | Secuado, Xelstrym |
| Sunovion Pharmaceuticals INC. | $26.22 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.94 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Portteus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.